In the BioHarmony Drug Report Database
Sacubitril
Entresto, Neparvis (sacubitril) is a small molecule pharmaceutical. Sacubitril was first approved as Entresto on 2015-07-07. It has been approved in Europe to treat heart failure. Entresto’s patents are valid until 2036-05-09 (FDA).
Trade Name
|
Entresto, Neparvis |
|---|---|
Common Name
|
sacubitril |
ChEMBL ID
|
CHEMBL3137301 |
Indication
|
heart failure |
Drug Class
|
Endopeptidase inhibitors |
Image (chem structure or protein)